AI Article Synopsis
- Rheumatoid arthritis (RA) is linked to high levels of special proteins called autoantibodies that can start the disease.
- Scientists found that some of these autoantibodies can actually help protect mice from arthritis instead of causing it.
- They also discovered that healthy people have special immune cells that decrease in number in RA patients, which might help explain how the disease develops.
Article Abstract
A hallmark of rheumatoid arthritis (RA) is the increased levels of autoantibodies preceding the onset and contributing to the classification of the disease. These autoantibodies, mainly anti-citrullinated protein antibody (ACPA) and rheumatoid factor, have been assumed to be pathogenic and many attempts have been made to link them to the development of bone erosion, pain and arthritis. We and others have recently discovered that most cloned ACPA protect against experimental arthritis in the mouse. In addition, we have identified suppressor B cells in healthy individuals, selected in response to collagen type II, and these cells decrease in numbers in RA. These findings provide a new angle on how to explain the development of RA and maybe also other complex autoimmune diseases preceded by an increased autoimmune response.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/ard-2023-225237 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impaired coagulation parameters in early RA are restored by effective antirheumatic therapy: a prospective pilot study.
RMD Open
December 2024
Rheumatology, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands
Objectives: To assess the effect of treatment on haemostatic parameters in patients with early rheumatoid arthritis (RA).
Methods: Patients with newly diagnosed RA started methotrexate and were randomised to additional conventional treatment, certolizumab pegol, abatacept or tocilizumab. Several biomarkers for haemostasis were analysed including parameters of the two global haemostatic assays-overall haemostatic potential (OHP) and endogenous thrombin potential (ETP), as well as single haemostatic factors-fibrinogen, prothrombin fragment 1+2 (F1+2), D-dimer, thrombin activatable fibrinolysis inhibitor (TAFI) and clot lysis time (CLT) in 24 patients at baseline, 12 and 24 weeks after the start of the treatment.
Impacts of Methylenetetrahydrofolate Reductase Genotypes on Hallux Valgus.
In Vivo
December 2024
Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.;
Background/aim: Hallux valgus (HV) is the most common deformity of the forefoot. Although HV has been strongly associated with a family history, its genetic underpinnings remain unclear. Few studies have examined the relationship between folic acid metabolism, which is critical in normal bone development, and HV.
View Article and Find Full Text PDFA Short Report on Prescription Monitoring in the Therapeutic Context of Rheumatoid Arthritis at an Italian Local Health Authority.
Int J Rheum Dis
January 2025
Pharmacy Department, Asl Napoli 3 Sud, Naples, Italy.
Association of N, N-diethyl-m-toluamide (DEET) with arthritis among adult participants.
PLoS One
December 2024
Department of General Medicine, Beijing TianTan Hospital, Capital Medical University, Beijing, China.
Background: N, N-diethyl-m-toluamide (DEET), an active ingredient prevalent in insect repellents, has its effects on human health under ongoing debate and scrutiny.
Objective: This study aimed to investigate the association between exposure to DEET and arthritis outcomes within the broader adult demographic, leveraging data obtained from the National Health and Nutrition Examination Survey (NHANES).
Methods: 3-diethyl-carbamoyl benzoic acid (DCBA) was used as a specific indicator of DEET exposure.
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.
Ann Rheum Dis
December 2024
Department of Rheumatology, Centre National de Référence des Maladies Auto-Immunes Rares, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France
Background: Targeted therapies have been associated with potential risk of malignancy, which is a common concern in daily rheumatology practice in patients with inflammatory arthritis (IA) and a history of cancer.
Objectives: To perform a systematic literature review to inform a Task Force formulating EULAR points to consider on the initiation of targeted therapies in patients with IA and a history of cancer.
Methods: Specific research questions were defined within the Task Force before formulating the exact research queries with a librarian.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!